AT&T Expands Quantum Partnership with D-Wave, Adding Enterprise Validation but Leaving Valuation Gap Unchanged

What happened

AT&T signed an agreement to expand its use of D-Wave's quantum annealing and cloud services across network operations, marking deepening enterprise adoption. The deal adds to growing commercial engagement following a $10 million Fortune 100 QCaaS contract disclosed in Q1 and a $20 million FAU system sale, which together drove record bookings. While the agreement reinforces D-Wave's relevance in production-grade optimization, it does not immediately resolve the $8 billion-plus valuation gap, given Q1 revenue of only $2.9 million and ongoing cash burn. The company's thesis still hinges on converting $42 million of remaining performance obligations into reported revenue and securing definitive CHIPS funding. The AT&T expansion offers incremental demand evidence but leaves the core financial overhang intact.

Implication

The AT&T deal confirms that D-Wave’s annealing technology is gaining traction with large enterprises beyond isolated pilots, which could gradually address booking concentration risk. However, with a market cap exceeding $8 billion against sub-$25 million trailing revenue, the stock still discounts rapid, flawless execution on booking-to-revenue conversion, gate-model development, and federal funding. Investors should monitor whether this deal translates into higher reported revenue in coming quarters and reduces dependence on the two anchor contracts. Until quarterly revenue consistently exceeds $10 million and CHIPS funding becomes definitive, current valuations leave limited margin for error. The thesis delta shifts from 'potential sell' to 'hold with tighter monitoring,' as the enterprise validation edge is incrementally positive but not yet sufficient to upgrade the rating.

Thesis delta

The AT&T agreement incrementally strengthens the demand narrative by demonstrating deeper large-enterprise commitment, reducing the risk that initial contracts were one-off. This shifts the thesis from 'potential sell' to 'hold with tighter monitoring,' as the commercialization path gains credibility but still lacks the revenue scale to justify the current premium. The stock remains a high-risk play on quantum adoption, now with a slightly firmer demand floor.